PMA device
Urovysion Bladder Cancer Kit
Abbott Molecular · Test, Fluorescence In Situ Hybridization (Fish), For Bladder Cancer Detection And Monitoring For Recurrence (NSD, Class III) · First FDA decision May 10, 2006, newest Jan 24, 2014Bladder cancer
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
0
Naming "Urovysion"
MAUDE reports
4
Brand "Urovysion", since 2015
PubMed studies
268
Mentioning "Urovysion"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Urovysion Bladder Cancer Kit
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- UROVYSION BLADDER CANCER KITPMA supplement
P030052-S012 · Decided Jan 24, 2014 · 148 days after receipt · Normal 180 Day Track No User Fee
Device type: Test, fluorescence in situ hybridization (fish), for bladder cancer detection and monitoring for recurrence (NSD) · Laboratory Medicine & Pathology
- UROVYSION BLADDER CANCER KITPMA supplement
P030052-S001 · Decided May 10, 2006 · 324 days after receipt · Normal 180 Day Track No User Fee
Device type: Test, fluorescence in situ hybridization (fish), for bladder cancer detection and monitoring for recurrence (NSD) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Screening Pap Smears and Pelvic Examinations for Early Detection of Cervical or Vaginal CancerNational determinationOn the books210.2Updated Sep 30, 2025
- Prostate Cancer Detection with IsoPSA®Local determinationIn effectL39284CGS Administrators, LLCUpdated Oct 30, 2026
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38586CGS Administrators, LLCUpdated May 11, 2026
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38684WPS Insurance CorporationUpdated Apr 10, 2026
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38647Noridian Healthcare Solutions, LLCUpdated Apr 7, 2026
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38576Palmetto GBAUpdated Apr 7, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Urovysion", any status and sponsor, newest update first.
No registered device study names "Urovysion".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Urovysion", and for the whole product code for context.
This brand
4 reports: 4 malfunction, 0 injury, 0 death
Whole product code NSD
4 reports: 4 malfunction, 0 injury, 0 death
Newest reports for this brand
- PROBECHEK UROVYSION CONTROL SLIDEMalfunction
3005248192-2020-00002 · Received Feb 24, 2020 · Event dated Jan 29, 2020
Device type: Test, Fluorescence In Situ Hybridization (Fish), For Bladder Cancer Detection And Monitoring For Recurrence (NSD)
Device problem as coded: Device Damaged Prior to Use
Patient problem as coded: No Patient Involvement
3005248192-2016-00004 · Received Jun 29, 2016 · Event dated May 31, 2016
Device type: Test, Fluorescence In Situ Hybridization (Fish), For Bladder Cancer Detection And Monitoring For Recurrence (NSD)
Device problem as coded: Defective Component
Patient problem as coded: No Patient Involvement
3005248192-2015-00013 · Received May 22, 2015 · Event dated May 5, 2015
Device type: Test, Fluorescence In Situ Hybridization (Fish), For Bladder Cancer Detection And Monitoring For Recurrence (NSD)
Device problem as coded: Break
Patient problem as coded: No Consequences Or Impact To Patient
1 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Urovysion"[tiab]. The summary above synthesizes these.
- Bladder Cancer, a Cytogenomic Update.
Ruggero A, Clark M, Lewkowski A, et al. · J Assoc Genet Technol · 2024
- Refined pancreatobiliary UroVysion criteria and an approach for further optimization.
Mettman D, Saeed A, Shold J, et al. · Cancer Med · 2021
- Utility of UroVysion Fluorescence in situ Hybridization in Improving the Diagnostic Performance of Urine Cytology.
Sharan KC, Srinivasan R, Uppal R, et al. · Acta Cytol · 2024
- Evaluation of UroVysion for Urachal Carcinoma Detection.
Hu Z, Ke C, Liu Z, et al. · Front Med (Lausanne) · 2020
- UroVysionTM Fluorescence In Situ Hybridization in Urological Cancers: A Narrative Review and Future Perspectives.
Ke C, Hu Z, Yang C · Cancers (Basel) · 2022Review
- Urinary Biomarkers In Bladder Cancer.
Costantini M, Gallo G, Attolini G · Methods Mol Biol · 2021
- UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives.
Nagai T, Naiki T, Etani T, et al. · Transl Androl Urol · 2021Review
- UroVysionࡊ fluorescence in situ hybridization (FISH) possibly has a high positive rate in carcinoma of non-urothelial lineages.
Ke C, Liu X, Wan J, et al. · Front Mol Biosci · 2023
- Chromosomal aberrations, visualized using UroVysion® fluorescence in-situ hybridization assay, can predict poor prognosis in formalin-fixed paraffin-embedded tissues of cholangiocarcinoma patients.
Ainthachot S, Sa-Ngiamwibool P, Thanee M, et al. · Hum Pathol · 2022Research Support, Non-U.S. Gov't
- "Indeterminate" UroVysion Fluorescence In Situ Hybridization Results.
Xu J, Westfall DE, Lopategui JR · Am J Clin Pathol · 2021
- Reflex UroVysion testing in suspicious urine cytology cases.
Ferra S, Denley R, Herr H, et al. · Cancer · 2009
- Optimizing UroVysion Fluorescence In-Situ Hybridization Reflex Testing in Atypical Urothelial Cell Diagnosis: A Comprehensive Cytomorphological Analysis.
Thuzar M, Flowers A, Takei H · Ann Clin Lab Sci · 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.